Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Titel:
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Auteur:
Dummer, Reinhard Ascierto, Paolo A Gogas, Helen J Arance, Ana Mandala, Mario Liszkay, Gabriella Garbe, Claus Schadendorf, Dirk Krajsova, Ivana Gutzmer, Ralf Chiarion Sileni, Vanna Dutriaux, Caroline de Groot, Jan Willem B Yamazaki, Naoya Loquai, Carmen Moutouh-de Parseval, Laure A Pickard, Michael D Sandor, Victor Robert, Caroline Flaherty, Keith T